Novel Heterocyclic Dpp-4 Inhibitors for the Treatment of Type 2 Diabetes.
2012
Abstract Novel deazaxanthine-based DPP-4 inhibitors have been identified that are potent (IC 50 3a resulted in the identification of compound ( S )- 4i , which displayed an improved in vitro and
ADMEprofile. Further enhancements to the PK profile were possible by changing from the deazahypoxanthine to the deazaxanthine template,
culminatingin compound 12g , which displayed good
ex vivoDPP-4 inhibition and a superior PK profile in rat, suggestive of once daily dosing in man.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
18
References
46
Citations
NaN
KQI